LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Novartis
Federation Francophone de Cancerologie Digestive
National Cancer Institute, Naples
EMD Serono
Sixth Affiliated Hospital, Sun Yat-sen University
Sanofi
Gustave Roussy, Cancer Campus, Grand Paris
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
NSABP Foundation Inc
University of Southampton
National Cancer Institute (NCI)